## **1** Outbreak of Chikungunya Fever in the Central Valley of Chiapas, Mexico.

# 2 Short title: Outbreak of Chikungunya in Chiapas, Mexico

- 3 Ana Luz Gonzalez-Perez<sup>1</sup>, Ana Vazquez<sup>2,3</sup>, Fernando de Ory<sup>3,4</sup>, Anabel Negredo<sup>2</sup>, Kenneth S.
- 4 Plante<sup>5</sup>, Jessica A. Plante<sup>5</sup>, Pedro M. Palermo<sup>6</sup>, Douglas Watts<sup>6</sup>, Maria Paz Sanchez-Seco<sup>2</sup>, Scott
- 5 C. Weaver<sup>5</sup>, Jose Guillermo Estrada-Franco<sup>7</sup>.

- <sup>7</sup> <sup>1</sup>Centro de Investigación y Estudios Avanzados en Salud Animal (CIESA), Universidad
- 8 Autónoma del Estado de México, Toluca, México.
- 9 <sup>2</sup> Laboratory of Arboviruses and Imported Viral Diseases, Centro Nacional de Microbiología,
- 10 Instituto de Salud Carlos III, Majadahonda, Spain.
- <sup>3</sup> National Microbiology Centre, Institute of Health Carlos III, Biomedical Research Networking
- 12 Centre for Public Health (CiberESP), Spain.
- <sup>4</sup> Laboratory of Serology, National Microbiology Centre, Institute of Health Carlos III,
- 14 Majadahonda, Madrid, Spain.
- <sup>5</sup> Institute for Human Infections and Immunity, World Reference Center for Emerging Viruses
- and Arboviruses, and Department of Microbiology & Immunology, University of Texas Medical
- 17 Branch at Galveston, Texas, United States of America
- <sup>6</sup> Border Biomedical Research Center, Department of Biological Sciences, University of Texas at
  El Paso, Texas, USA

- <sup>7</sup> Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, Tamaulipas,
- 21 Mexico.
- 22 \* Corresponding author
- 23 Email: jestradaf@ipn.mx

# 24 Abstract

Chikungunya virus (CHIKV) was isolated from humans in an outbreak of a febrile illness during 25 July and August 2015 in the central valleys of Chiapas, Mexico. Sera obtained from 80 patients 26 were tested for CHIKV RNA by reverse transcriptase polymerase chain reaction (RT-PCR) and 27 28 for IgM and IgG antibodies by an enzyme linked immunoassay and a commercial indirect immunofluorescence test for CHIKV and dengue virus (DENV). Of the 80 patients, 67 were 29 positive, including 50 for RNA and 17 for IgM. In addition, one patient was coinfected with 30 31 CHIKV-DENV and 40 patients were positive for IgG antibody to DENV. The clinical manifestations included a high fever, polyarthralgia, headache, myalgia, rash, digestive 32 disorders, conjunctivitis, and adenopathy associated with cervical and axillary inguinal regions. 33 34 Complete nucleotide sequences of two of the CHIKV isolates showed that they belonged to the 35 Asian lineage but did not group with other Mexican CHIKV isolates from the Chiapas coast. Our 36 findings documented that different Asian lineage strains of CHIKV were circulating 37 simultaneously during the 2015 outbreak in the Central Valley of Chiapas, Mexico. The 2024 38 cases suggest an explosive scenario of re-emergence of thousands of new Chikungunya and 39 dengue fever (DENF) cases associated with deaths, and a dangerous increase of the four DENV serotypes throughout the Americas, especially in South American countries that have shown a 40

high influx of human migration to southern Mexico. In Mexico, the state of Chiapas and othersouthern regions are the most vulnerable.

43

## 44 Author Summary:

The first ever recorded outbreak of Chikungunya virus (CHIKV) in the highlands (central valley 45 of Chiapas) Mexico took place in 2015. Clinical data from 80 infected patients together with 46 information provided from virus isolates offered a vision of the diseased and their response 47 linked to different variables such as age, gender, association with pre-existing diseases of some 48 49 patients, including CHIKF-DENF co-infection. The origins of the Tuxtla Gutierrez CHIKV viruses isolated in the study, including other Mexican isolates, were traced to viruses circulating 50 in regions of Asia in Micronesia and Philippines. Also, we call the attention of the influx of 51 52 migrants coming from countries having current explosive outbreaks of CHIKV and DENV in the Americas and into southern Mexico. Further we discuss vulnerabilities and point out specially to 53 54 the geographic location of Chiapas State and its strategic position for attracting the human migrant population. 55

56

57 **Keywords:** Chikungunya, Chiapas, Mexico, viral RNA, IgM and IgG antibody, Dengue.

58

59 Introduction

Chikungunya virus (CHIKV), *Togaviridae*, genus *Alphavirus*, is an arthropod-borne virus
transmitted peri-domestically by *Aedes (Stegomyia) aegypti* and *Ae. (Stegomyia) albopictus*mosquitoes [1]. At least four genetic lineages of CHIKV have been described including West
African, East/ Central/South African, Asian, and Indian Ocean [2].

The first documented outbreak of chikungunya fever (CHIKF) associated with autochthonous transmission in the Americas was reported during December of 2013 on the Caribbean Island of St. Martin [3]. In 2014, the Pan American Health Organization (PAHO) estimated more than a million cases of CHIKF in 50 countries in the Americas [4]. The disease manifestations include fever >38°C, rash and severe arthralgia that is disabling, and patients may also experience a chronic phase with continuing articular and periarticular inflammation lasting for months or years that is seldom fatal [5].

In 2004, CHIKV began to cause major outbreaks that affected humans in substantial 71 portions of Africa, the Indian Ocean Basin, Asia, Europe, and more recently the Americas [6]. 72 The spread of CHIKV was exacerbated by infected people travelling from regions of active virus 73 74 transmission [7]. Millions were affected, and this scenario was further complicated in some areas, due in part to the adaptive mutations in the CHIKV viral genome that resulted in changes 75 in the E1 (A226V) [8,9] and E2 (several substitutions) glycoproteins [10]. These mutations 76 77 enhanced infection of Ae. albopictus mosquitoes, and an increase in the vector competence of this species for CHIKV. As a result, European outbreaks of CHIKF in Italy and France and in 78 79 islands of the Indian Ocean [11] were associated with the distribution of Ae. albopictus mosquitoes, thus demonstrating the emerging importance of this species as a potential vector of 80 CHIKV [12]. The ability of both Ae. aegypti and Ae. albopictus to serve as efficient vectors 81 represents a highly efficient vectorial system for the transmission of CHIKV worldwide [13]. 82

83	In Mexico, the first traveler case of CHIKF was reported in Jalisco state in May 2014
84	[14], and the first autochthonous case was diagnosed in Coastal Chiapas, Mexico, in November
85	2014 [15]. In a period of 10 years (2014 – 2024), Mexico's Health Ministry recorded 776 cases
86	of CHIKF in the State of Chiapas [16]. According to the Pan American Health Organization
87	(PAHO), 273,685 CHIKF cases were recorded in 2022 and 410,754 CHIKF cases were recorded
88	during 2023 in 17 countries of the Americas, including 419 deaths, representing a 43% increase
89	in the number of cases. In 2024, 186,274 cases with 60 deaths had been recorded by the
90	epidemiological week 14 [17]. Clearly there is an escalation of CHIKV cases reported mainly in
91	South American countries with a high migratory trend in the south Chiapas Mexican border [18].
92	The occurrence during early 2015 of unusual dengue-like cases in the medical
93	community of the Metropolitan region of Tuxtla Gutierrez, the capital State of Chiapas,
94	suggested the outbreak represented an extension of the first epidemic of Mexican CHIKV
95	recorded in the State's coastal region [19]. Here we describe the epidemiology, clinical, and
96	molecular observations of the first major epidemic of CHIKF that occurred during the summer of
97	2015 in the central valleys of Chiapas, Mexico. Phylogenetic studies indicated that the outbreaks
98	in Mexico were caused by strains of the CHIKV Asian lineage [20], and Ae. aegypti was
99	incriminated as the principal vector [21].
100	

## 100

# 101 Study area: The Central Valley of Chiapas

The study was carried out in the Central Valley of Chiapas during July and August of
2015 at three sites, two health care facilities: 1) at the General Hospital "Dr. Belisario
Domínguez", Institute of Security and Social Services of State Workers ISSSTE, located in
Tuxtla Gutiérrez (16 ° 45'11 "N 93 ° 06'56" W; altitude 522 meters), and including patients from

106	the municipalities of Berriozabal, Chiapa de Corzo, and Suchiapa (Fig 1 and Fig 2) the Rural
107	Hospital of Solidarity Opportunities, Mexican Institute of Social Security IMSS Number 31,
108	located in Ocozocoautla de Espinoza (16 ° 45'00 "N 93 ° 22'00" W; 818 altitude meters) at 18.7
109	km west of Tuxtla Gutierrez. The third site was Miguel Álvarez del Toro Zoo (ZooMAT) located
110	in Tuxtla Gutierrez.
111	The climate in the Central Valley is warm and humid, with an average annual
112	temperature of 25.4°C and annual rainfall of 1,200 mm [22].
113	Patient Selection Criteria
114	Blood samples were collected from patients who presented at the health care facilities
115	and samples from suspected zoo workers, using a case definition of suspected CHIKF including
116	a fever >38°C and arthritis/arthralgia with an acute onset that was not explained by other medical
117	conditions, and residing in or visiting the epidemic areas during two weeks prior to the onset of
118	illness [23].
119	Patient Data Collection
120	A questionnaire was designed to record the following variables: a) Epidemiological and
121	demographic: age, sex, contact with relatives, neighbors, friends at school and/or work contacts,
122	previous days of illness, and recent travel; b) Clinical: detailed description of the symptoms and
123	signs; c) Laboratory: blood biometry, serology, and RT-PCR results; d) Environmental:
124	community environment characteristics.
125	Sample Collection
126	Venipuncture blood samples were collected and centrifuged at 1207 x g to obtain serum that was
127	aliquoted and stored at -80°C. Samples were sent for diagnostic testing and nucleotide

sequencing to the World Reference Center for Emerging Viruses and Arboviruses at the

- 129 University of Texas Medical Branch (UTMB), Galveston, Texas, USA; to the National Center
- 130 for Microbiology (CNM), Instituto de Salud Carlos III (ISCIII), Majadahonda, Spain and to the
- 131 Virology Laboratory at the University of Texas at El Paso (UTEP), Texas.

## **Blood Biometry**

- 133 Hematological values were determined using a hematology analyzer Advia® 120 (Siemens
- 134 Healthcare Diagnostics, Erlangen, Germany).

### 135 Molecular assays

- 136 They were conducted through two protocols: 1) Viral RNA was extracted from sera using the
- 137 ZR-96 Viral RNA Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's
- protocol. A one-step quantitative reverse transcription PCR (qRT-PCR) was performed by using
- the TaqMan RNA-to-Ct 1-step Kit (Applied Biosystems, San Francisco, CA, USA) [24].
- 140 2) To extend the screening, RNA was extracted from the sera using the QIA amp viral RNA kit
- 141 (Qiagen, Valencia, CA) following the manufacturer's protocol. Next, RT-PCR targeting the
- alphavirus nsP4 gene was used to detect CHIKV RNA, as previously described [25]. The results
- 143 were confirmed with a specific nested PCR for CHIKV, which was directed to the E1 gene [26].
- 144 Subsequently, all samples were screened by qRT-PCR for CHIKV (Realstar CHIKV RT-PCR
- 145 kit, Altona Diagnostic, Hamburg, Germany). All negative samples were also tested for other
- 146 etiologic agents, including bunyaviruses, arenaviruses, hantaviruses, and phleboviruses using in-
- 147 house RT-PCR techniques [27-29].

148 Methods

## 149 **Ethical considerations**

The Bioethics Committee of the Faculty of Medicine of the Autonomous University of
the State of Mexico (Approval No. 011/2015) approved the study. Written informed consent was

obtained from all patients who enrolled in this study. Minor patients participated with the prior 152 authorization of their parents. Patients' personal information was anonymized before analyzing 153 154 patient data, including demographic characteristics, clinical signs and symptoms. Serology assays 155 All samples were tested for CHIKV antibody using enzyme-linked immunosorbent assay 156 157 (ELISA) [30]. An IgM antibody-capture (ELISA) was performed using a chimeric Eilat-CHIK 158 containing the nonstructural protein genes of Eilat virus and structural protein genes of CHIKV, 159 which produces virions indistinguishable structurally from those of CHIKV [31]. Additionally, 160 sera were screened by a commercial indirect immunofluorescent (IIF) anti-Chikungunya Virus 161 IIFT IgG and IgM (Euroimmun AG, Lübeck, Germany) [32, 33] and the IIF assay Arboviral Fever Mosaic IgG and IgM, Euroimmun, Germany [34, 35]. Also, the samples were tested to 162 163 determine antibody titers by a dengue IgM capture ELISA, Panbio® and dengue indirect IgG ELISA, Panbio®, Queensland, Australia [36]. 164

## 165 Sequencing and phylogenetic analysis

166 Two CHIKV positive sera (ID 2107 and ID 2115) were selected for Illumina® Bio Systems nucleotide sequencing. Available CHIKV sequences encoding both open reading frames of the 167 168 genome were retrieved from the Genbank database. CHIKV sequences without published 169 references were excluded. A total of 143 representative strains were selected for the phylogenetic 170 analysis including our CHIKV strains 2107 and 2115. Sequences were trimmed to remove the 5' 171 and 3' untranslated genome regions (UTRs) and were aligned using Clustal Omega in MegAlign Pro version 12.0.0 (DNASTAR Inc, Madison, WI). Maximum likelihood analysis was performed 172 using the phangorn package [37] in R version 3.4.2 [38]. The GTR+G+I model of nucleotide 173 substitution was selected from the 24 options analyzed as part of the model test analysis in 174

175	phangorn based on minimizing the AIC score. Bootstrapping was performed with 1,000
176	iterations. The resulting tree was visualized using iTOL version 4.3.3 [39].
177	Results
178	Among the sera obtained from 80 patients, 46 were collected in Tuxtla Gutierrez, 31 in
179	Ocozocoautla de Espinoza and 3 from the municipalities of Chiapa de Corzo, Berriozabal and
180	Suchiapa (Fig 1). Of the 46 samples collected in Tuxtla Gutierrez, 7 were from ZooMAT
181	workers. We conducted two assay protocols on the 80 samples at UTMB and AEVI-CNM-ISCIII

and obtained 50 positives for CHIKV RNA RT-PCR and 17 samples were positive by ELISA for

183 CHIKV IgM antibody. The 17 IgM positive samples were reconfirmed by IIF for Chikungunya

184 IgM antibody. Of the seven samples from patients related to the ZooMAT, three were positive

185 for CHIKV RNA by RT-PCR, qRT-PCR and three were positives CHIKV IgM or IgG antibody

186 by ELISA.

187 The assay of the 80 serum samples by RT-PCR for arenavirus, hantavirus, bunyavirus and

188 phlebovirus viral RNA was negative. One CHIKV RNA positive sample and one CHIKV RNA

negative were positive for dengue IgM antibody by ELISA. Also, the results revealed that 40 of

190 the 80 patients had DENV IgG antibody as evidence of a previous infection.

191 Viral isolation

Seventeen of the 50 CHIKV PCR-positive samples were tested for virus isolation in C6/36 cells.
CHIKV was isolated from all seventeen samples based on the detection of cytopathic effects on
day 6 post-inoculation and were also positive for CHIKV by IFA as more conclusive results.

**195 Sequencing and Phylogenetic Analysis** 

196 The genomes of two CHIKV isolates, ID 2107 and ID 2115, were fully sequenced and the

assembled complete genome sequences were submitted to GenBank under the accession

198	numbers PQ261036 and PQ261037. A phylogenetic analysis was performed, along with 143
199	geographically and temporally diverse CHIKV sequences from GenBank encompassing Asian,
200	East/Central/South African (ECSA), Indian Ocean and West African lineage strains of CHIKV
201	(S1 Table). A maximum-likelihood tree was generated using complete open reading frame
202	sequences with the 5' and 3' UTRs removed. The results showed that both isolates (ID 2107 and
203	ID 2115) clustered with the Asian lineage and with the other CHIKV isolates obtained from the
204	Americas and the Caribbean (Fig 3). The uncorrected pairwise distances between both 2107 and
205	2115 and the other Asian lineage isolates from the Americas and Caribbean ranged from 0.0003
206	(0.03% nucleotide sequence divergence) to 0.0016. Their distance to the other Asian lineage
207	strains varied from 0.0015 for strains thought to immediately precede the introduction of CHIKV
208	to the Caribbean, such as the Yap 2013 isolate, and up to 0.0279 for the 1973 Indian isolate.
209	Their distances from the ECSA strains ranged from 0.0559 to 0.0654, and their distances from all
210	including West African strains ranged from 0.1565 to 0.1583.
211	There were 110 variable nucleotide positions among the Asian lineage CHIKV sequences from
212	the Americas. The 2107 and 2115 strains differed from the consensus sequence at 11 positions
213	(five in 2107, two in 2115, and four mutual positions for both strains 2107 and 2115) (Table 1).
214	Only one of these changes encoded an amino acid substitution in nsP3 (H377P) which was in the
215	hypervariable region and was unique to strain 2115 (Table 1). It should be noted, however, that
216	all of the West African lineage isolates analyzed possess a leucine at this position and five of the
217	26 Asian lineages isolates from Asia did not contain a deletion in this codon 377. Neither strain
218	2107 nor 2115 encoded the Ae. albopictus-adaptive E1 [9] or E2 [11] substitutions identified in
219	some of the Indian Ocean Lineage CHIKV strains.

220	Amino acid variation was also analyzed among CHIKV isolates ID 2107 and ID 2115,
221	and the other eight Mexican CHIKV isolates from other studies with complete coding sequences
222	available in GenBank (Table 2). Other than the nsP3 H377P change detected in 2115, only one
223	amino acid in nsP3 varied among Mexican isolates: L340S, detected only in CH-R-1950.
224	Interestingly, although the Mexican isolates were evenly split between valine and alanine at E3-
225	113, it is worth noting that all other strains considered in the phylogeny possessed a valine at this
226	position except for the 2014 isolate from the British Virgin Islands isolate, which contains an
227	alanine.
228	Blood biometrics
229	Blood count abnormalities were found among the CHIKV positive patients. Samples had
230	changes in one or all three cell types (leukopenia, lymphopenia and neutropenia) that help to
231	differentiate CHIKF, especially in the acute phase [40] (Table 3).
232	Epidemiological variables
233	Demographic
234	Of the 67 CHIK-positive patients, 40% were male and 60% were female. Most of the
235	cases of CHIKF occurred among the 10-59 years old group (Table 4). Among occupations, 34
236	(51%) were workers (professional, employee, crafts), 19 (28%) students, 11 (16%) housemakers,
237	two (3%) retired, and one (2%) was a preschooler patient.
238	Clinical-epidemiological findings
239	During the initial phase, 40% of CHIKV-positive patients were misdiagnosed by the
240	primary care medical staff. The treating health personnel recorded signs and symptoms due to
241	other etiologies, including 60% who were diagnosed with DENF, 25% with other types of
242	illnesses such as respiratory diseases (15%), stress and chronic exhaustion (5%), common

243	headache (3%), food allergies (2%); and only 15% were properly diagnosed as CHIKF cases.
244	CHIKV positive patients signs/symptoms included fever 38 °C - 41.0 °C ( $\bar{x}$ = 38.3 °C) with 2-5
245	days of evolution. The dominant signs/symptoms observed in the patients were polyarthralgia in
246	67 people (83.3%; 95% CI 75%-91%) of 1-5 days duration, headache 53 patients (66%; 95 CI
247	55%-76%) evolving within a range of 1-7 days, myalgia 46 patients (57.4%; 95% CI 46%-68%)
248	in 2-3 days, conjunctivitis 42 individuals (52.4%; 95% CI 41%-63%) progressing in 1-4 days,
249	and exanthema 42 patients (52.4%; 95% CI 41%-63%) unfolding in 1-6 days (Table 5).
250	Symmetric bilateral arthralgia was present in 52 individuals (64.8%; 95% CI 54%-75%) and a
251	severe degree of pain was observed in 36 individuals (45%;95% CI 34%-55%). Nine (11.7%;
252	95% CI 5.2%-18%) patients had pain in all joints of the body. In 33 persons affected joints
253	involved the upper (41.3%;95% CI 30%-52%) (shoulder, elbow, wrist, hand, fingers) and in 23
254	(29%; 95% CI 19%-38%) patients lower limbs (hip, knee, ankle. foot, toes). Acute cutaneous
255	manifestations were present in 42 patients (52.4%; 95% CI 41%-63%), including a rash that
256	presented as maculopapular and pruritic, pruritic, maculopapular and diffuse (Table 6). Bullous
257	and pruritic rash was observed in a school-age patient. The rash developed mainly in arms in 30
258	persons (37.6%; 95% CI 27%-48%), 16 patients in legs (20.3%; 95% 11%-29%), and in 15
259	persons (19.1%; 95% CI 10%-27%) (Table 7). Five patients reported having burning sensation in
260	the skin, three of them in the soles and two in the palms (Table 7).
261	Adenopathy was observed in 28 CHIKF patients (35.1%; 95% CI 24%-45%) 41.8%,
262	including cervical (retroauricular, neck), axillary and inguinal region. Twelve patients involved a
263	single anatomical site and 16 in two or more anatomical areas. Four CHIKF patients required
264	hospitalization and 14 persons reported comorbidities, including three patients with diabetes, five

with hypertension, two persons with diabetes and hypertension, one with muscular dystrophy,

one patient disc herniation and cystitis, one patient with Horner syndrome and, one withhypertension and one with vertigo.

#### 268 Environment characteristics

Seventy four percent CHIKF cases lived in urban areas and 26% lived in suburban-rural 269 areas. Fifty-one percent had contact with CHIKF like homes, work, school or in the same 270 271 locality. Fifty-four percent had periodic contact with bodies of water. The characteristics of the 272 water for 40% of the cases was sewage, 30% clean running water (streams, lakes) and 6.6% 273 standing water. Twenty two positive patients lived, worked or studied near a dump or cemetery. 274 Fifty three patients lived near areas with abundant vegetation. All of these premises were located at distance of  $\leq 150$  meters of radius. At the ZooMAT we obtained six positive samples wild 275 forest reserve area with a large population of vertebrate wild fauna and many invertebrates 276

277 particularly *Aedes albopictus* and *Ae. aegypti* mosquitoes in abundance within the reserve.

278

### 279 Discussion

We report the first CHIKV isolates from febrile patients in the Central Valley of Chiapas 280 State, Mexico, including five municipalities: Tuxtla Gutiérrez, Ocozocoautla de Espinoza, 281 282 Berriozabal, Chiapa de Corzo, and Suchiapa. Isolates were obtained from patients who resided about 130 km away from the first Mexican autochthonous recorded CHIKF case in 2014 [16]. 283 284 Phylogenetic analysis showed that our CHIKV isolates belong to the Asian lineage that 285 was circulating in the Americas [3]. Our isolates were found to be closely related to the CHIKV sequences from the Bahamas 2014 (KY435470), Mexico 2015 CHR1950 (MG921596) and 286 287 Mexico 2014 InDRE 51 (KP851709), but clustering in a different subclade. According to the 288 terminology of Sahadeo et al, 2017 [2], our isolates grouped in the Asian/American lineage,

which is defined by two amino acid substitutions: E2 V368A and 6K L20M. When comparing 289 290 our isolates with the consensus sequence, 11 point mutations were found in the nsP1, nsP2, nsP3 291 and capsid genes, presenting more variants than observed in the structural proteins E2 and E1. In nsP1, we observed two synonymous mutations in both isolates (2107 and 2115). nsP2 had one 292 synonymous mutation only in the 2107 sequence. The nsP3 gene had four mutations, three of 293 294 which were synonymous in the 2107 sequence and one nonsynonymous mutation in isolate 2115. 295 Sequence 2115 mutation is classified as transition and transversion in region 378 of nsP3. There 296 is a change of histidine (hydrophobic amino acid, no polarity) by proline (amino acid hydrophilic 297 with positive polarity), which is a novel finding. Substitution of a hydrophobic residue with a polar amino acid could represent possible structural changes, as observed in other alphaviruses 298 299 [41], which affects in vitro replication and viral pathogenesis. The observation warrants future 300 studies on CHIKV.

The CHIKV isolates of this study did not group with other isolates from coastal Chiapas 301 302 which have the E2 V113A substitution as observed for CHIKV isolates in the British Virgin Islands sequences [2]. We also found differences in the non-structural (nsP3 and nsP4) and 303 structural proteins (E2 and E3) of our strains. These findings showed that different strains of the 304 305 CHIKV Asian lineage were circulating simultaneously in the Central Valley of Chiapas. In our study, CHIKF cases were diagnosed among people of wide age ranges, from 306 307 nursling to octagenarians ( $\overline{x} = 33$  years), supporting the expected outcome for the age 308 distribution of cases due to recent introduction of CHIKV into the completely naïve population 309 of the Americas. A higher proportion of our cases occurred in the age ranges 1-9, 30-39 and 40-310 49, unlike the data of the Mexican Epidemiological Surveillance System SINAVE/DGC [17], the 311 most affected age group was 25-29 years in 2015. Our findings of clinical manifestations

including high fever, polyarthralgia, headache, myalgia, rash, and digestive disorders, matched 312 with the clinical signs/symptoms of CHIKF outbreaks (see table 5 for Confidence 95% intervals) 313 314 involving the Asian lineage [42-46]. Interestingly, we also observed signs/symptoms that were rarely described in other studies: conjunctivitis of 1-4 days of duration in 62.7% and adenopathy 315 in 41.8%, the later associated with cervical (retroauricular, neck), axillary, and inguinal region. 316 317 Other studies have reported the development of adenopathies in CHIKF as being uncommon [47,48] whereas such changes are commonly found in other alphaviruses patients, such as 318 319 o'nyong-nyong fever [49]. Also, unlike other studies we found 62.7% of patients with mainly 320 maculopapular and pruritic rash and bullous and pruritic in a schooler patient. One sign that appeared nearly only in women at a 4:1 ratio with men was facial hyperemia. Others were ulcers 321 (17.9%), hemorrhages (6.0%), gum pain (11.9%), burning skin (7.5%) and jaundice (3.0%). The 322 323 clinical signs of the patient from whom strain 2115 was obtained with the mutation in the nsP3 324 region were symmetric bilateral arthralgia with severe joint pain in the shoulder, trunk, back and 325 hip; pruritic maculopapular rash in the chest, trunk and abdomen, adenopathy, burning sensation on the skin, high and low back pain, dizziness, nausea, vomiting, difficulty breathing, and 326 327 lymphopenia. As previously mentioned, clinical signs such as adenopathy, skin burning, and 328 difficulty breathing have rarely been associated with CHIKV infection [11,42,43,45]. In our study, clinical signs and symptoms were observed more frequently in women 329

(60%) than in men, which potentially reflects greater exposure to mosquito bite risk due to the
fact of household activities, clothing practices, and/or greater willingness to seek medical care.
Also, during the initial phase, we observed that 40% of our CHIKV-positive patients were
misdiagnosed by the primary care medical staff. The treating health personnel recorded signs and
symptoms due to other etiologies, including DENF, respiratory diseases, stress and chronic

exhaustion, common headache, food allergies; and only 15% were properly diagnosed as CHIKF
cases. A significant decrease in labor productivity due to absenteeism and disabling pain was
also observed, suggesting a serious effect associated with CHIKF at the family household
economy.

Misdiagnosis can greatly affect the clinical picture of infected patients. This would impact the evolution from DENF to severe dengue hemorrhagic fever (DHF) disease and the risks unsuitable medication of CHIKF patients with arthralgia-alleviating nonsteroidal antiinflammatory drugs, which could lead to severe bleeding in patients with DHF or

thrombocytopenia [50].

Chikungunya continues to be a latent and important public health problem, especially in
regions lacking proper medical care and diagnostic facilities that characterize the Mexican
Republic and mosquito vectorial populations that are abundant.

The SINAVE in 2015 reported 683 cases in Chiapas, out of the total number of CHIKF patients registered throughout the country. Between 2016-2018, 18 cases of CHIKF were documented in Chiapas. No cases were recognized between 2019-2021 and until 2022-2023 only two cases, one per year, were reported. As of the epidemiological week 27, 2024, no cases of the CKIKF had been documented [17].

In Mexico, there is an apparent decrease in the circulation and transmission of CHIKV which can be explained mainly by two facts, a) the CDC-PAHO guidelines proposing to test only 5% of the supposedly suspected CHIKF cases in health settings [23] and b) protection considering that the first explosive outbreaks occurred in 2015- 2016 that resulted in herd immunity protection by the exposed population. In this context, we assumed that the true burden of CHIK disease in this Mexican region is unknown and that confirmed cases could be under-

reported. It is likely that the burden of CHIK disease is underreported because several positive
cases were missed by surveillance systems due to clinical similarities with other endemic viral
diseases (dengue, Zika, etc.) [17] in the study area.

361 The current picture reported in other geographical regions of the Americas have revealed explosive outbreaks of CHIKV, particularly in south American countries, suggesting a latent or 362 even progress outbreaks of CHIKV forecasted for Mexico. According to PAHO data from 363 364 January 1 to September 10, 2024, 11,574,374 cases of CHIKF and more than 6,542 deaths were 365 documented from 20 countries most from the South American region. In 2023, 410,754 including 419 deaths, cases were reported, this was an increase in more than 135,000 cases as 366 367 compared with the previous 2022 year, with the most affected countries being Brazil, Paraguay, 368 Argentina, Uruguay and Bolivia [17, 51]. Of the five countries, Brazil stands out as one of the most important contributing human migratory numbers into south Mexico, including the Chiapas 369 370 State region (UN, IOM Annual Report 2024) [18], with trends pointing to in land migratory 371 movements towards the Mexico-US northern border. We believe the picture during 2024 is complemented by an ongoing DENF outbreak near the south Mexican border, including the State 372 373 of Chiapas, with an increase of 354 % DENF cases only in the July month of 2024 [22,211 374 DENF cases] as compared to 2023 (4,892 DENF cases) [51]. The actual scenario recorded in the 375 Mexican Republic reinforces the notion that hundreds of cases of CHIKF might be hidden under 376 the dengue umbrella. During our studies in 2015, we found at least one coinfected case of CHIKV-DENV and half of the positive CHIKF cases showed IgG DENV antibodies suggesting 377 378 that in the 2024 Mexican scenario, DENV diagnosis should be complemented throughout a 379 concerted approach of differential diagnostics with CHIKF by the different regional health entities. We consider this to be an essential approach to help clarify some of the enigmas 380

associated with the explosive arboviral outbreaks going on in many regions of Mexico and 381 elsewhere in the continent. All in all, the scope of CHIKV in Mexico likely represents an 382 383 underestimation of CHIKF cases. Therefore, it is advisable that differential diagnostics be implemented by the health agencies to distinguish between DENV (flavivirus) and CHIKV 384 385 (alphavirus) infection. It is important to stress that in the case of any foreseen outbreak of 386 CHIKF in the Chiapas region, an important component of the surveillance policies should focus 387 on molecular approaches to monitor for novel mutations that might increase the vector 388 competence and therefore lead to an increase infection rate among the human vertebrate host in 389 the region. This is going to help determine the true regional CHIKV burden and even other arbovirus etiologies in the Mexican southern regions and elsewhere. 390 **Funding sources** 391 392 This work was part of the PhD studies of the first author (ALGP) at the Universidad Autónoma 393 del Estado de México (UAEM) and was supported by Consejo Nacional de Humanidades, 394 Ciencias y Tecnologías (CONAHCYT) grant 231888, México. Also, the study was supported in part by a Grant 2U54MD007592 from the National Institutes on Minority Health and Health 395 396 Disparities (NIMHD), a component of the National Institutes of Health (NIH). JGEF was 397 supported by SIP-IPN grants, 20221576, 20230712, 20231063 and 20242330. 398 399 Acknowledgements 400 The authors convey their sincere thanks to Teodora Minguito, María Ángeles Murillo, Lourdes 401 Hernández and Francisca Molero.

#### 402 **Conflicts of Interest**

403 The authors declare no conflict of interest.

# 404 Author Bio

405	MC. Gonzalez-Perez is a doctoral student at the Universidad Autónoma del Estado de
406	México, where she has been investigating emerging and reemerging zoonotic diseases. Her
407	doctoral studies have an emphasis on management of pathogens of biosafety level 3 and 4.
408	
409	Author contributions
410	Conceptualization: Ana Luz Gonzalez-Perez, Jose Guillermo Estrada-Franco
411	Design experiments: Ana Luz Gonzalez-Perez, Jose Guillermo Estrada-Franco
412	Data curation: Ana Luz Gonzalez-Perez
413	Funding acquisition: Jose Guillermo Estrada-Franco, Scott Weaver, Maria Paz Sanchez-Seco
414	Investigation: Ana Luz Gonzalez-Perez
415	Methodology: Ana Luz Gonzalez-Perez, Ana Vazquez, Maria Paz Sanchez-Seco, Scott Weaver
416	Lab molecular diagnostics: Ana Luz Gonzalez-Perez, Jessica A. Plante, Kenneth S. Plante, Scott Weaver,
417	Douglas Watts, María Paz Sanchez-Seco, Ana Vazquez, Anabel Negredo, Pedro M. Palermo, Jose
418	Guillermo Estrada-Franco
419	Lab serological diagnosis: Ana Luz Gonzalez-Perez, Fernando de Ory, Jessica A. Plante, Douglas Watts,
420	Jose Guillermo Estrada-Franco
421	Project administration: Jose Guillermo Estrada-Franco
422	Resources: Ana Luz Gonzalez-Perez, Scott Weaver, Maria Paz Sanchez-Seco, Douglas Watts, Jose
423	Guillermo Estrada-Franco
424	Software: Jessica A. Plante, Kenneth S. Plante
425	Writing – original draft: Ana Luz Gonzalez-Perez, Jose Guillermo Estrada-Franco
426	Writing – review & editing: Ana Luz Gonzalez-Perez, Douglas Watts, Scott Weaver, Fernando de Ory,
427	Jose Guillermo Estrada-Franco

# 429 Supporting information

- 430 S1 Table. Chikungunya strains list of isolates. (XLSX)
- 431
- 432

433	References
-----	------------

- Weaver SC. Arrival of chikungunya virus in the new world: prospects for spread and impact
   on public health. PLoS Negl Trop Dis 2014; 8:e2921
- 436 2. Sahadeo NSD, Allicock OM, De Salazar PM, Auguste AJ, Widen S, Olowokure B, et al.
- 437 Understanding the evolution and spread of chikungunya virus in the Americas using

438 complete genome sequences. Virus Evol. 2017; 3(1), vex010

- 439 3. European Centre for Disease Prevention and Control (ECDC). Rapid Risk Assessment.
  440 Autochthonous cases of chikungunya fever on the Caribbean Island, Saint Martin. 11
- 441 December 2013. Stockholm: ECDC;2013.
- 442 4. Pan American Health Organization (PAHO), World Health Organization (WHO). 2018.
- 443 Number of reported cases of chikungunya fever in the Americas, by country or territory
- 444 2017 (to week noted) epidemiological week / EW 51 (Updated as of 22 December 2017).
- 445 Cited May 30, 2024, available at: <u>https://www3.paho.org/hq/dmdocuments/2017/2017-ago-</u>
- 446 <u>18-phe-CHIKV-cases-ew-33.pdf</u>
- 447 5. Pialoux G, Gaüzère B-A, Jauréguiberry S, Strobel M. Chikungunya, an epidemic
  448 arbovirosis. Lancet Infect Dis. 2007; 7(5):319-27.
- 6. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus.
  Lancet. 2012; 379(2):662–71.

451	7.	Centers for Disease Control and Prevention (CDC). Chikungunya fever diagnosed among
452		international travelers-United States, 2005-2006.MMWR Morb Mortal Wkly Rep. 2006;
453		Sep 29;55(38):1040-2.
454	8.	Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya
455		virus affects vector specificity and epidemic potential. PLoS Pathog. 2007; 3(12): e201.
456	9.	Vazeille M, Moutailler S, Coudrier D, Rousseaux C, Khun H, Huerre M, et al. Two
457		chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different
458		patterns of infection in the mosquito, Aedes albopictus. PLoS One. 2007; 2:e1168.
459	10	Tsetsarkin KA, Chen R, Yun R, Rossi SL, Plante KS, Guerbois M, et al. Multi-peaked
460		adaptive landscape for chikungunya virus evolution predicts continued fitness optimization
461		in Aedes albopictus mosquitoes. Nat Commun. 2014; 5:4084.
462	11.	Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, et al.
463		Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral
464		Res. 2013; 99:345–70.
465	12	Reiter P, Fontenille D, Paupy C. Aedes albopictus as an epidemic vector of chikungunya
466		virus: another emerging problem? The Lancet Infect Dis. 2006; 6(8),463–464.
467	13	Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of a
468		zoonotic arbovirus. J Gen Virol. 2007 Sep;88(Pt 9):2363-2377.
469	14	Rivera-Ávila RC. Chikungunya fever in Mexico: confirmed case and notes on the
470		epidemiologic response. Salud Publica Mex. 2014; 56:402-404.
471	15	Centro Nacional de Programas Preventivos y Control de Enfermedades. Declaratoria de
472		emergencia epidemiológica EE-2-2014 para el estado de Chiapas ante el primer caso de
473		transmisión autóctona de enfermedad por virus de chikungunya. [Internet]. 2014 [Cited

474	January 2024].
475	http://www.cenaprece.salud.gob.mx/programas/interior/emergencias/descargas/pdf/Declar
476	atoria Emergencia Chiapas Chikungunya.pdf
477	16. Dirección General de Epidemiología (DGE). Sistema Nacional de Vigilancia
478	Epidemiológica (SINAVE). Boletín epidemiológico. Histórico de semanas epidemiológicas
479	52. 2024 Dirección de Información Epidemiológica, DGE/SINAVE/SALUD. 2024 [Cited
480	May 29 2024]. Available in: https://www.gob.mx/salud/acciones-y-programas/historico-
481	boletin-epidemiologico
482	17. Pan American Health Organization (PAHO), World Health Organization (WHO). 2024.
483	Epidemiological actualization: chikungunya in the Americas region. April 22, 2024.
484	Washington, D.C. OPS/OMS. Cited Jun 20, 2024, available at:
485	https://www.paho.org/en/documents/epidemiological-update-chikungunya-region-
486	americas-22-april-2024
487	18. IOM. International Organization for Migration. Migration trends in the Americas. July-Sep
488	2023 Mexico. Annual report. Available at:
489	https://rosanjose.iom.int/sites/g/files/tmzbdl1446/files/documents/2023-12/en-tendencias-
490	julio-setiembre-de-2024.pdf
491	19. Kautz TF, Díaz-González EE, Erasmus JH, Malo-García IR, Langsjoen RM, Patterson EI,
492	et al. Chikungunya virus as cause of febrile illness outbreak, Chiapas, Mexico, 2014. Emerg
493	Infect Dis. 2015; Nov 21(11):2070-3.
494	20. Díaz-Quiñonez JA, Ortiz-Alcántara J, Fragoso-Fonseca DE, Garcés-Ayala F, Escobar-
495	Escamilla N, Vázquez-Pichardo M, et al. Complete genome sequences of chikungunya virus

- 496 strains isolated in Mexico: first detection of imported and autochthonous cases. Genome
  497 Announc. 2015; May 7;3(3):e00300-15.
- 498 21. Díaz-González EE, Kautz TF, Dorantes-Delgado A, Malo-García IR, Laguna-Aguilar M,
- 499 Langsjoen RM, et al. First report of *Aedes aegypti* transmission of chikungunya virus in the
- 500 Americas. Am J Trop Med Hyg. 2015 Dec;93(6):1325-9.
- 501 22. Instituto Nacional de Estadística y Geografía. Conociendo Chiapas. (2013) México: INEGI
- 502[CitedApril302022]Disponibleen:
- http://internet.contenidos.inegi.org.mx/contenidos/Productos/prod\_serv/contenidos/espanol/bvineg
   i/productos/estudios/conociendo/Chiapas.pdf
- 23. Pan American Health Organization. PAHO/CDC. Preparedness and response of
   chikungunya virus in the Americas. Washington DC: PAHO 2011; 149 pages.
- 507 24. Powers AM, Roehrig JT. Alphaviruses. Methods Mol Biol. 2010; 665:17–38.
- 508 25. Sánchez-Seco MP, Rosario D, Quiroz E, Guzmán G, Tenorio A. A generic nested-RT-PCR
- 509 followed by sequencing for detection and identification of members of the alphavirus genus.
- 510 J Virol Methods. 2001; 95(1-2), 153–161.
- 511 26. Collao X, Negredo AI, Cano J, Tenorio A, de Ory F, Benito A, et al. Different lineages of
  512 chikungunya virus in Equatorial Guinea in 2002 and 2006. Am J Trop Med Hyg, 2010;
  513 82:505–507.
- 514 27. Sanchez-Seco MP, Echevarria JM, Hernandez L, Estevez D, Navarro-Mari JM, Tenorio A.
- 515 Detection and identification of toscana and other phleboviruses by RT-nested-PCR assays 516 with degenerated primers. J Med Virol. 2003; 71:140–149.
- 517 28. Sánchez-Seco MP, Rosario D, Domingo C, Hernandez L, Valdés K, Guzmán MG, et al.
- 518 Generic RT-nested-PCR for detection of flaviviruses using degenerated primers and internal

- control followed by sequencing for specific identification. J Virol Methods. 2015; 126:101109.
- 521 29. Ledesma J, Fedele CG, Carro F, Lledó L, Sánchez-Seco MP, Tenorio A, et al. Independent
- 522 lineage of lymphocytic choriomeningitis virus in wood mice (Apodemus sylvaticus), Spain.
- 523 Emerg Infect Dis. 2009 Oct;15(10):1677-80.
- 30. Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Diagnostic procedures for viral,
  rickettsial, and chlamydial infections (N. J. Schmidt & E. W. Emmons, eds.), 6th Ed. 1989;
  pp. 797-855, Washington, D.C.: American Public Health Association.
- 527 31. Erasmus JH, Needham J, Raychaudhuri S, Diamond MS, David W. C. Beasley DWC, et al.
- 528 Utilization of an Eilat virus-based chimera for serological detection of chikungunya 529 infection. PLOS Negl Trop Dis. 2015; 9(10): e0004119.
- 32. Litzba N, Schuffenecker I, Zeller H, Drosten C, Emmerichc P, Charrel R, et al. Evaluation
  of the first commercial chikungunya virus indirect immunofluorescence test. J Virol
- 532 Methods 2008; Apr 149(1):175–179-9.
- 33. Burdino E, Calleri G, Caramello P, Ghisetti V. Unmet needs for a rapid diagnosis of
  chikungunya virus infection. Emerg Infect Dis. 2016; 22(10), 1837-1839.
- 535 34. Huzly D, Hanselmann I, Schmidt-Chanasit J, Panning M. High specificity of a novel zika
- 536 virus ELISA in European patients after exposure to different flaviviruses. Euro Surveill.
- 537 2016; 21(16):pii=30203
- 538 35. Granger D, Gómez LJ, Schimek M, Dubbels M, Mosquera JA, Christensen J, et al. Zika
- 539 virus antibody detection: evaluation of three different serologic methodologies. 2016; Abstr
- 540 32nd Clin Virol Symp, Daytona Beach, Florida, USA.

541	36. Cuzzubbo AJ, Vaughn DW, Nisalak A, Solomon T, Kalayanarooj S, Aaskov J, et al.
542	Comparison of PanBio Dengue Duo IgM and IgG capture ELISA and venture technologies
543	dengue IgM and IgG dot blot. J Clin Virol. 2000 Apr;16(2):135-44.
544	37. Schleip KP. Phangorn: Phylogenetic analysis in R. Bioinformatics. 2011; 27(4) 592-593.
545	38. R Core Team. R: A language and environment for statistical computing. R Foundation for
546	Statistical Computing, 2017, Vienna, Ausitria. URL https://www.R-project.org/
547	39. Letunic I, Bork P. Interactive Tree of Life (iTOL) v4: recent updates and new developments.
548	Nucleic Acids Res. 2019; April 1.
549	40. Meshram CD, Phillips AT, Lukash T, Shiliaev N, Frolova EI, Frolov I. Mutations in
550	hypervariable domain of venezuelan equine encephalitis virus nsP3 protein differentially
551	affect viral replication. J Virol. 2020 Jan 17;94(3). pii: e01841-19
552	41. Mattar S, Miranda J, Pinzon H, Tique V, Bolanos A, Aponte J, et al. Outbreak of
553	chikungunya virus in the north Caribbean area of Colombia: clinical presentation and
554	phylogenetic analysis. J Infect Dev Ctries. 2015; 9: 1126±32.
555	42. Sahadeo N, Mohammed H, Allicock OM, Auguste AJ, Widen SG, Badal K, et al. Molecular
556	characterization of chikungunya virus infections in Trinidad and comparison of clinical and
557	laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015;
558	9:e0004199.
559	43. Danis-Lozano R, Diaz-Gonzalez EE, Trujillo-Murillo KC, Caballero-Sosa S, Sepulveda-
560	Delgado J, Malo-Garcia IR, et al. Clinical characterization of acute and convalescent illness
561	of confirmed chikungunya cases from Chiapas, S. Mexico: A cross sectional study. PLoS
562	ONE. 2017; 12(10):e0186923.

563	44. Cigarroa-Toledo N, Blitvich BJ, Cetina-Trejo RC, Talavera-Aguilar LG, Baak-Baak, CM,
564	Torres-Chablé OM, et. al. Chikungunya virus in febrile humans and Aedes aegypti
565	mosquitoes, Yucatan, Mexico. Emerging infectious diseases. 2016; 22(10), 1804–1807.
566	45. Macpherson C, Noe ÈT, Fields P, Jungkind D, Yearwood K, Simmons M, et al. Clinical
567	and serological insights from the Asian lineage Chikungunya outbreak in Grenada, 2014:
568	An observational study. Am J Trop Med Hyg. 2016; 95: 890±893.
569	46. Norman FF, Monge-Maillo B, Perez-Molina J-A, de Ory F, Franco L, Sánchez-Seco M-P,
570	et al. Lymphadenopathy in patients with chikungunya virus infection imported from
571	Hispaniola: case reports. J Travel Med. 2015; 22: 272±275.
572	47. Keny MS, Pereira IA, Desa SB, Gomes EJ. Painful cervical lymphadenopathy: an unusual
573	presentation of chikungunya. Int J Appl Basic Med Res. 2014; 4: 47±9.
574	48. Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba R, et al.
575	O'nyongnyong fever in south-central Uganda, 1996±1997: clinical features and validation
576	of a clinical case definition for surveillance purposes. Clin Infect Dis. 1999; 29: 1243±50.
577	49. Weaver SC. Urbanization and geographic expansion of zoonotic arboviral diseases:
578	mechanisms and potential strategies for prevention. Trends Microbiol. 2013;21(8):360–363.
579	50. Laoprasopwattana K, Kaewjungwad L, Jarumanokul R, Geater A. Differential diagnosis of
580	chikungunya, dengue viral infection and other acute febrile illnesses in children. Pediatr
581	Infect Dis J. 2012;31:459–463.
582	51. OPS/OMS-PLISA data. (cited: October 23, 2023). Available at:

583 https://www3.paho.org/data/index.php/es/

- 584 Address for correspondence: José Guillermo Estrada-Franco, Centro de Biotecnología
- 585 Genómica, Instituto Politécnico Nacional, Boulevard del Maestro s/n. Colonia Narciso Mendoza.
- 586 88710, Reynosa, Tamaulipas, México; email: jestradaf@ipn.mx
- 587

# Tables and Figures

588 Fig 1. Map of Chiapas, Mexico showing the sites where serum samples were obtained to test for Chikungunya virus in 2015.

589



595

596

597 Fig 2. The results for testing sera sample obtained from suspected chikungunya fever cases by a commercial indirect

- immunofluorescent antibody assay during an outbreak of chikungunya fever in 2015 in Chiapas, Mexico.
- 599
- 600
- 601









- A. CHIKV positive ID 2154
- B. CHIKV positive ID 6-29

**Fig 3.** Phylogenetic analysis of CHIKV isolates obtained from patients during an outbreak of chikungunya fever in Chiapas, Mexico.



- 627 Maximum-likelihood tree based on the full genome sequences (minus the 5' and 3' UTRs) of 143 geographically and temporally
- 628 diverse strains of CHIKV from GenBank, along with strains 2107 and 2115 (highlighted with red and bold text). Branch lengths are
- 629 scaled relative to substitutions. Bootstrapping was performed with 1,000 iterations; values ≥80 are represented as closed black
- 630 circles at the node in the full phylogenetic tree (right), and are listed as text in the expanded view of the Asian lineage strains from
- 631 the Americas and Caribbean (left).
- 632
- 633

634 Table 1. Mutations in complete chikungunya virus ORF nucleotide sequences for chikungunya virus isolates (ID 2017 and ID 2115)

from Chiapas patients during an outbreak 2015 in Chiapas, Mexico.

636

Nucleotide Change	Protein	Amino Acid Change	Isolate ID
	Location		
T480C	nsP1 135	Silent (L)	2107, 2115
C1526T	nsP1 483	Silent (Y)	2107, 2115
A2279T	nsP2 199	Silent (L)	2107
T4172C	nsP3 32	Silent (G)	2107
T4727C	nsP3 217	Silent (H)	2107
T5009C	nsP3 311	Silent (F)	2107
A5206C	nsP3 377	H>P	2115
C7819T	Capsid 88	Silent (P)	2115
C8998T	E2 156	Silent (Y)	2107
T9265C	E2 245	Silent (N)	2107, 2115
C10225T	E1 81	Silent (F)	2107, 2115

637 Summary of nucleotide-level variation between chikungunya virus isolates 2107 and 2115 and 43 other New World Asian lineages

638 strains of chikungunya virus. Nucleotide and amino acid positions are based on Accession KP164567.1

639

641 Table 2. Amino acid variation among Mexican chikungunya virus (CHIKV) isolates obtained during an outbreak of chikungunya

- fever in 2015 in Chiapas, Mexico.

								Strains			
Protein name	AA position	2107	2115	 CH0008	CH0045	CH0072	InDRE 4CHIK	InDRE 51CHIK	LI0031	TA0006	CH-R-1950
nsP3	340	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Ser
nsP3	377	His	Pro	His	His	His	His	His	His	His	His
nsP4	274	Asn	Asn	Asn	Asn	Asn	Asp	Asn	Asn	Asn	Asn
nsP4	399	Ser	Ser	Ser	Ser	Ser	Ser	Cys	Ser	Ser	Ser
nsP4	432	Met	Met	Met	Met	Met	Thr	Met	Met	Met	Met
E3	42	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Ser
E2	113	Val	Val	Ala	Ala	Ala	Val	Val	Ala	Ala	Val

644 Summary of amino acid variation between all Mexican isolates of CHIKV with full coding sequences deposited in Gene Bank, in 645 addition to 2107 and 2115. Consensus determined by alignment of 45 New World Asian lineage strains of CHIKV. Bold indicates non-646 consensus reside. Amino acid positions are based on Accession KP164567.1.

**Tabla 3.** Hematological abnormalities in 67 chikungunya fever patients during an outbreak of chikungunya fever in 2015 in Chiapas,

## 658 Mexico.

Blood formula	% (n=67)
Leukopenia (<4.50 miles/µl)	13 (9)
Leukocytosis (>10.50 miles/µl)	9 (6)
Erythrocytosis (>5.0 million/µI)	67 (11)
Hemoglobin Low (<12.5 g/dl)	13 (9)
Hematocrit Low (<37.0 %)	2 (1)
Lymphopenia (<24 miles/UI)	52 (35)
Lymphocytosis (>38 miles/UI)	12 (8)
Monocytopenia (<4.0 miles/UI)	68 (11)
Monocytosis (>10.0 miles/UI)	8.5 (6)
Thrombocytopenia (<50.0 miles/µl)	7.4 (5)

- **Table 4.** Incidence of chikungunya virus (CHIKV) infection by age and gender during a chikungunya fever outbreak during 2015
- in Chiapas, Mexico.

Age	Infected CHIKV	Infected CHIKV	Total Infected
(Years)	Female (%)	Male (%)	CHIKV%
1-9	4 (67)	2 (3)	6 (100)
10-19	10 (53)	5 (26)	15 (79)
20-29	5 (41)	4 (33)	9 (75)
30-39	6 (50)	3 (25)	9 (75)
40-49	10 (63)	5 (31)	15 (94)
50-59	6 (55)	4 (36)	10 (91)

60-69	1 (100)	0 (N/A)	1 (100)
70-79	0	0 (N/A)	0 (0)
80-89	0	2 (67)	2 (67)
Total	42	25	67

662

663

**Table 5.** Clinical manifestation of the patients infected during a chikungunya fever outbreak of 2015 in Chiapas, Mexico.

Signs/	% Female		95% CI		%(n=67)	95% CI	% Total	95% CI
Symptoms		(n=67)		% Male			(n=80)	
Arthralgias	62.7 (42)	52.4 (42)	41%-63%	37.3 (25)	31.4 (25)	21%-41%	83.7 (67)	75%-91%
Headache	60.4 (32)	40.1 (32)	29%-50%	39.6 (21)	26.5 (21)	17%-36%	66 (53)	55%-76%
Myalgia	56.2 (26)	32.7 (26)	22%-42%	43.5 (20)	25.3 (20)	16%-34%	57.4 (46)	46%-68%
Conjunctivitis	59.5 (25)	31.4 (25)	21%-41%	40.5 (17)	21.6 (17)	12%-30%	52.4 (42)	41%-63%
Exanthema	64.3 (27)	33.9 (27)	23%-44%	35.7 (15)	19.1 (15)	10%-27%	52.4 (42)	41%-63%
Depression	63.4 (26)	32.7 (26)	22%-42%	36.6 (15)	19.1 (15)	10%-27%	51.2 (41)	40%-62%
Abdominal pain	69.5(25)	31.4 (25)	21%-41%	30.5 (11)	14.1 (11)	7%-21%	45 (36)	34%-55%
Retro eye pain	57.6 (19)	24 (19)	15%-33%	42.4 (14)	17.9 (14)	9.9%-26%	41.3 (33)	30%-52%
Adenopathy	71.4 (20)	25.3 (20)	16%-34%	28.6 (8)	10.4 (8)	4.3%-17%	35.1 (28)	24%-45%
Photophobia	50.0 (14)	17.9 (14)	10%-25%	50.0 (14)	17.9 (14)	9.9%-26%	35.1 (28)	24%-45%
Nausea	70.4 (19)	24 (19)	15%-33%	29.6 (8)	10.4 (8)	4.3%-17%	33.9% (27)	23%-44%
Tonsillitis	66.7 (18)	22.8 (18)	14%-32%	33.3 (9)	11.7 (9)	5.2%-18%	33.9% (27)	23%-44%
Paresia	58.3 (14)	17.9 (14)	10%-26%	41.7 (10)	12.9 (10)	6.1%-20%	30.2 (24)	20%-40%
Cough	50.0 (11)	14.1 (11)	7%-21%	50.0 (11)	14.1 (11)	7%-21%	27.7 (22)	18%-37%
Diarrhea	68.2 (15)	19.1 (15)	10%-27%	31.8 (7)	9 (7)	0.3%-15%	27.7 (22)	18%-37%
Nasal	66.7 (14)	17.9 (14)	10%-26%	33.3 (7)	9 (7)	0.3%-15%	26.5 (21)	17%-36%
congestion								
Dyspnoea	60.0 (12)	15.4 (12)	8%-23%	40.0 (8)	10.4 (8)	4.3%-17%	25.3 (20)	16%-34%
Otitis	64.7 (11)	14.1 (11)	7%-21%	35.3 (6)	8 (6)	2.6%-13%	21.6 (17)	12%-30%
Facial	82.4 (14)	17.9 (14)	9.9%-26%	17.6 (3)	4.3 (3)	0.6%-8.7%	21.6 (17)	12%-30%
hyperemia		. ,			. ,			
Petechiae	62.5 (10)	12.9 (10)	6.1%-20%	37.5 (6)	8 (6)	2.6%-13%	20.3 (16)	11%-29%
Inappetence	73.3 (11)	14.1 (11)	7%-21.0%	26.7 (4)	5.5 (4)	1.2%-10%	19.1 (15)	10%-27%

Abnormal	53.3 (8)		4.3%-17%		9 (7)	0.3%-15%		10%-27%
muscle		10.4 (8)		46.7 (7)			19.1 (15)	
sensitivity								
Pharyngitis	78.6 (11)	14.1 (11)	7.0%-21.0%	21.4 (3)	4.3 (3)	0.6%-8.7%	17.9 (14)	9.9%-26%
Puke	75.0 (9)	11.7 (9)	5.2%-18%	25 (3)	4.3 (3)	0.6%-8.7%	15.4 (12)	7.9%-23%
Ulcers	41.7 (5)	7 (5)	1.9%-12%	58.3 (7)	9 (7)	0.3%-15%	15.4 (12)	7.9%-23%
Agitation	72.7 (8)	10.4 (8)	4.3%-17%	27.3 (3)	4.3 (3)	0.6%-8.7%	14.1 (11)	7.0%-21%
Dizziness	60.0 (6)	8 (6)	2.6%-13%	40 (4)	5.5 (4)	1.2%-10%	12.9 (10)	6.1%-20%
Swelling of limbs	55.5 (5)	6.7 (5)	1.9%-12%	44.6 (4)	5.5 (4)	1.2%-10%	11.7 (9)	5.2%-18%
Drowsiness	66.7 (6)	8 (6)	2.6%-13%	33.3 (3)	4.3 (3)	0.6%-8.7%	11.7 (9)	5.2%-18%
Gum pain	50 (4)	5.5 (4)	1.2%-10%	50 (4)	5.5 (4)	1.2%-10%	10.4 (8)	4.3%-17%
Tremors	62.5 (5)	6.7 (5)	1.9%-12%	37.5 (3)	4.3 (3)	0.6%-8.7%	10.4 (8)	4.3%-17%
Burning in skin	80.0 (4)	5.5 (4)	1.2%-10%	20 (1)	1.8 (1)	0.2%-4.7%	6.7 (5)	1.9%-12%
Bleeding	75 (3)	4.3 (3)	0.6%-8.7%	25 (1)	1.8 (1)	0.2%-4.7%	5.5 (4)	1.2%-10%
Jaundice	100 (2)	3 (2)	0.1%-6.0%	N/A(0)	0 (0)	0.2%	3 (2)	0.1%-6.0%
Confusion	100 (2)	3 (2)	0.1%-6.0%	N/A(0)	0 (0)	0.2%	3 (2)	0.1%-6.0%

665

CI 95 % Confidence interval

666

667 **Table 6.** Characteristics of the arthralgia for chikungunya fever cases during an outbreak of in 2015 in Chiapas, Mexico.

Characteristic arthralgia	% (n=67)	% (n=80)	95% CI
Distribution			
Arthralgia bilateral	77.6 (52)	64.8 (52)	54%-75%
Arthralgia unilateral	22.4 (15)	19.1 (15)	10%-27%
Arthralaia symmetrical	77.6 (52)	64 8 (52)	54%-75%
Annagia symmetrica	11.0 (32)	04.0 (32)	547677576
Degree of pain			
Mild Pain	5.9 (4)	5.5 (4)	1.2%-10%
Moderate Pain	40.3 (27)	33.9 (27)	23%-44%
Severe Pain	53.7 (36)	45 (36)	34%-55%

49.2 (33)	41.3 (33)	200/ 520/
	-	30%-52%
C (4)	E E (4)	1.20/ 1.00/
6 (4)	5.5 (4)	1.2%-10%
8.9 (6)	8.0 (6)	2.6%13%
32.8 (22)	27.7 (22)	18%-37%
22.3 (15)	19.1 (15)	10%-27%
14.9 (10)	12.9 (10)	6.1%-20%
34.3 (23)	29 (23)	19%-38%
25.3 (7)	9% (7)	0.3%-15%
23.8 (16)	20.3% (16)	11%-29%
23.8 (16)	20.3% (16)	11%-29%
23.8 (16)	20.3% (16)	11%-29%
8.9 (6)	8.0% (6)	2.6%1.3%
8.9 (6)	8.0% (6)	2.6%1.3%
7.4 (5)	6.7% (5)	1.9%-12%
25.3 (17)	21.6% (17)	12%-30%
4.4 (3)	4.3% (3)	0.6%-8.7%
10.4 (7)	9 (7)	0.3%-15%
13.4 (9)	11.7% (9)	5.2%-18%
	8.9 (6)         32.8 (22)         22.3 (15)         14.9 (10)         34.3 (23)         25.3 (7)         23.8 (16)         23.8 (16)         23.8 (16)         8.9 (6)         8.9 (6)         7.4 (5)         25.3 (17)         4.4 (3)         10.4 (7)         13.4 (9)	8.9 (6) $8.0 (6)$ $32.8 (22)$ $27.7 (22)$ $22.3 (15)$ $19.1 (15)$ $14.9 (10)$ $12.9 (10)$ $34.3 (23)$ $29 (23)$ $25.3 (7)$ $9% (7)$ $23.8 (16)$ $20.3% (16)$ $23.8 (16)$ $20.3% (16)$ $23.8 (16)$ $20.3% (16)$ $8.9 (6)$ $8.0% (6)$ $8.9 (6)$ $8.0% (6)$ $7.4 (5)$ $6.7% (5)$ $25.3 (17)$ $21.6% (17)$ $4.4 (3)$ $4.3% (3)$ $10.4 (7)$ $9 (7)$ $13.4 (9)$ $11.7% (9)$

671 **Table 7.** Characteristics of the exanthema in 42 patients of the 67 positive chikungunya fever cases during an outbreak of in 2015 in

## 672 Chiapas, Mexico.

Characteristic exanthema	% (n=42)	% (n=80)	95% CI	
Distribution				
Maculopapular	7.14 (3)	4.3 (3)	0.6%-8.7%	
Maculopapular and Pruritic	23.8 10)	12.9 (10)	6.1%-20%	
Pruritic	21.4 (9)	11.7 (9)	5.2%-18%	
Bulloso and Pruritic	2.4. (1)	1.8 (1)	0.2%-4.7%	
Difuse	7.1 (3)	4.3% (3)	0.6%-8.7%	
Difuse and Pruritic	2.4 (1)	1.8% (1)	0.2%-4.7%	
Anatomical sites exanthema				
Face	11.9 (5)	6.7 (5)	1.9%-12%	
Neck	2.3 (1)	1.8 (1)	0.2%-4.7%	
Trunk	33.3 (14)	17.9 (14)	9.9%-26%	
Arms	71.4 (30)	37.6 (30)	27%-48%	
Hand	7.1 (3)	4.3 (3)	0.6%-8.7%	
Chest	11.9 (5)	6.7% (5)	1.9%-12%	
Abdomen	35.7 (15)	19.1% (15)	10%-27%	
Back	19 (8)	10.4% (8)	4.3%-17%	
Legs	38.1 (16)	20.3% (16)	11%-29%	
Feet and Soles	4.7 (2)	3% (2)	0.1%-6%	

Entire Body	2.3 (1)	1.8% (1)	0.2%-4.7%

674

4 CI 95 % Confidence interval

![](_page_37_Figure_1.jpeg)